NORLAND MEDICAL SYSTEMS INC
SC 13D/A, 2000-01-18
LABORATORY ANALYTICAL INSTRUMENTS
Previous: ALLMERICA FINANCIAL CORP, SC 13G, 2000-01-18
Next: RISK CAPITAL HOLDINGS INC, 8-K, 2000-01-18



                                                                    Page 1 of 11


                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                  SCHEDULE 13D

                   Under the Securities Exchange Act of 1934
                               (Amendment No. 3)

                         NORLAND MEDICAL SYSTEMS, INC.
                                (Name of Issuer)

                                  Common Stock
                         (Title of Class of Securities)

                                  656031-10-1
                                 (CUSIP Number)


                               Reynald G. Bonmati
                                 Premium Point
                             New Rochelle, NY 10801
                                (914) 576--1595

                 (Name, Address and Telephone Number of Person
               Authorized to Receive Notices and Communications)

                               December 31, 1999
            (Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report
the  acquisition  that is the subject of this  Schedule  13D, and is filing this
schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-2(g), check
the following box [ ].

Note:  Schedules  filed in paper format shall include a signed original and five
copies of this  schedule,  including  all  exhibits,  should  be filed  with the
Commission. See Section 240.13d-7(b) for other parties to whom copies are to be
sent.

* The  remainder  of this cover page shall be filled out for a person's  initial
filing on this form with respect to the subject class of securities, and for any
subsequent  amendment  containing  information  which  would  alter  disclosures
provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
"filed" for the  purpose of Section 18 of the  Securities  Exchange  Act of 1934
("Act") or otherwise  subject to the  liabilities of that section of the Act but
shall be subject to all other provisions of the Act(however, see the Notes).


<PAGE>

CUSIP NO. 656031-10-1                                    Page 2 of 11

                                  SCHEDULE 13D

- -------------------------------------------------------------------------------
1             NAMES OF REPORTING PERSONS
              I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

              Norland Partners, L.P.
- -------------------------------------------------------------------------------
2             CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE
              INSTRUCTIONS) (a) ( )
                            (b) (x)
- -------------------------------------------------------------------------------
3             SEC USE ONLY

- -------------------------------------------------------------------------------
4             SOURCE OF FUNDS (SEE INSTRUCTIONS)

              OO
- -------------------------------------------------------------------------------
5             CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
              ITEMS 2(d) or 2(e) (  )
- -------------------------------------------------------------------------------
6             CITIZENSHIP OR PLACE OF ORGANIZATION

              A Delaware limited partnership
- -------------------------------------------------------------------------------
NUMBER OF     7     SOLE VOTING POWER
SHARES
BENEFICIALLY
OWNED BY
EACH REPORTING
PERSON
WITH                0
             ------------------------------------------------------------------
              8     SHARED VOTING POWER

                    0

             ------------------------------------------------------------------
              9     SOLE DISPOSITIVE POWER

                    0

             ------------------------------------------------------------------
             10     SHARED DISPOSITIVE POWER

                    0
- -------------------------------------------------------------------------------
11           AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

             0

- -------------------------------------------------------------------------------
12           CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
             SHARES (SEE INSTRUCTIONS)(  )

- -------------------------------------------------------------------------------
13           PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

             0%
- -------------------------------------------------------------------------------
14           TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

             PN
- -------------------------------------------------------------------------------

<PAGE>

CUSIP NO. 656031-10-1                                    Page 3 of 11

                                  SCHEDULE 13D

- -------------------------------------------------------------------------------
1            NAMES OF REPORTING PERSONS
             I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

             Novatech Management Corporation (the stockholders of which are
               Reynald G. Bonmati and Albert S. Waxman)

- -------------------------------------------------------------------------------
2            CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
             (SEE INSTRUCTIONS)     (a) ( )
                                    (b) (x)
- -------------------------------------------------------------------------------
3            SEC USE ONLY

- -------------------------------------------------------------------------------
4            SOURCE OF FUNDS (SEE INSTRUCTIONS)

             00
- -------------------------------------------------------------------------------
5            CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
             ITEMS 2(d) or 2(e) (  )
- -------------------------------------------------------------------------------
6            CITIZENSHIP OR PLACE OF ORGANIZATION

             A Delaware corporation
- -------------------------------------------------------------------------------
             7    SOLE VOTING POWER
NUMBER OF
SHARES
BENEFICIALLY      0
OWNED BY
EACH
REPORTING
PERSON
WITH
             ------------------------------------------------------------------
             8    SHARED VOTING POWER

                  0
             ------------------------------------------------------------------
             9    SOLE DISPOSITIVE POWER

                  0

             ------------------------------------------------------------------
             10   SHARED DISPOSITIVE POWER

                  0

- -------------------------------------------------------------------------------
11           AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

             0
- -------------------------------------------------------------------------------
12           CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
             SHARES (SEE INSTRUCTIONS) (  )

- -------------------------------------------------------------------------------
13           PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

             0%
- -------------------------------------------------------------------------------
14           TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

             CO
- -------------------------------------------------------------------------------

<PAGE>

CUSIP NO. 656031-10-1                                    Page 4 of 11

                                  SCHEDULE 13D


- -------------------------------------------------------------------------------
1            NAMES OF REPORTING PERSONS
             I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

             Bones, L.L.C. (the managing members of which are Reynald G. Bonmati
             and Hans Schiessl)

- -------------------------------------------------------------------------------
2            CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
             (SEE INSTRUCTIONS)     (a) ( )
                                    (b) (x)
- -------------------------------------------------------------------------------
3            SEC USE ONLY

- -------------------------------------------------------------------------------
4            SOURCE OF FUNDS (SEE INSTRUCTIONS)

             00

- -------------------------------------------------------------------------------
5            CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
             ITEMS 2(d) or 2(e) (  )
- -------------------------------------------------------------------------------
6            CITIZENSHIP OR PLACE OF ORGANIZATION

             A Delaware limited liability company
- -------------------------------------------------------------------------------
             7   SOLE VOTING POWER
NUMBER OF
 SHARES
BENEFICIALLY     10,234,833
OWNED BY
EACH
REPORTING
PERSON
WITH
             ------------------------------------------------------------------
             8   SHARED VOTING POWER

                 500,000


             ------------------------------------------------------------------
             9   SOLE DISPOSITIVE POWER

                 10,234,833

             ------------------------------------------------------------------
             10  SHARED DISPOSITIVE POWER

                 500,000


- -------------------------------------------------------------------------------
11           AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

             10,734,833
- -------------------------------------------------------------------------------
12           CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
             SHARES (SEE INSTRUCTIONS) (  )

- -------------------------------------------------------------------------------
13           PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

             41.4%
- -------------------------------------------------------------------------------
14           TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)


             00
- -------------------------------------------------------------------------------



<PAGE>


CUSIP NO. 656031-10-1                                    Page 5 of 11

                                  SCHEDULE 13D

- -------------------------------------------------------------------------------
1            NAMES OF REPORTING PERSONS
             I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

             Albert S. Waxman
- -------------------------------------------------------------------------------

2            CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
              (a) ( )
              (b) (x)
- -------------------------------------------------------------------------------
3             SEC USE ONLY

- -------------------------------------------------------------------------------

4             SOURCE OF FUNDS (SEE INSTRUCTIONS)

              00

- -------------------------------------------------------------------------------

5             CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
              ITEMS 2(d) or 2(e) (  )

- -------------------------------------------------------------------------------
6             CITIZENSHIP OR PLACE OF ORGANIZATION

              United States citizen
- -------------------------------------------------------------------------------
NUMBER OF
SHARES        7    SOLE VOTING POWER
BENEFICIALLY
OWNED BY
EACH REPORTING
PERSON             1,685,578
WITH
              -----------------------------------------------------------------
              8    SHARED VOTING POWER

                   0


              -----------------------------------------------------------------
              9    SOLE DISPOSITIVE POWER

                   1,685,578

              -----------------------------------------------------------------
              10   SHARED DISPOSITIVE POWER

                   0

- -------------------------------------------------------------------------------
11            AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

              1,685,578

- -------------------------------------------------------------------------------
12            CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN
              SHARES (SEE INSTRUCTIONS)(  )

- -------------------------------------------------------------------------------
13            PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

              6.5%
- -------------------------------------------------------------------------------
14            TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

              IN
- -------------------------------------------------------------------------------

<PAGE>

CUSIP NO. 656031-10-1                                    Page 6 of 11


                           Statement on Schedule 13D/A

         This Amendment amends and supplements the Statements on Schedule 13D of
the undersigned filed with the Securities and Exchange Commission on January 11,
1999,  April 12,  1999 and June 17, 1999  (collectively,  as last  amended,  the
"Original  Statement") with respect to the beneficial  ownership by such persons
of shares of common  stock,  $.0005  par  value per  share ("Common  Stock"), of
Norland Medical Systems, Inc., a Delaware corporation (the "Issuer"). The filing
of this Amendment is occasioned by certain  transfers of the shares as described
herein.  Except as set forth below,  the  information  contained in the Original
Statement is unchanged.

         As of December 31, 1999, Norland Partners,  L.P.  ("Norland  Partners")
distributed  all of the 7,735,201  shares of Common Stock of the Issuer owned by
it to its  partners  in the  following  amounts:  (i)  35,266  shares to John W.
Buckman,  a former  associate  of  Novatech  Management  Corporation  ("Novatech
Management"),  the general partner of Norland Partners; (ii) 2,975,106 shares to
Novatech Management; (iii) 2,397,846 shares to Novatech Ventures L.P. ("Novatech
Ventures"); and (iv) 2,326,983 shares to certain other partners (individuals and
entities) of Norland Partners otherwise unrelated to Issuer.

         Novatech Management,  after acquiring the 2,975,106 shares from Norland
Partners on December 31, 1999,  immediately  distributed such shares, along with
369,049 shares it previously owned, to its two shareholders,  Albert Waxman, who
received  1,685,578  shares,  and Reynald G.  Bonmati,  who  received  1,685,577
shares.  Mr. Bonmati has filed his own amended  Schedule 13D with respect to his
beneficial ownership of securities of the Issuer.

         Novatech Ventures, after acquiring the 2,397,846 shares of Common Stock
on December 31, 1999 from Norland Partners,  immediately distributed such shares
to its partners in the following  amounts:  (i) 847,454 shares to Bones,  L.L.C.
("Bones"); (ii) 240,524 shares to Michael Huber, a Director of the Issuer; (iii)
295,290  shares to Mary Baker,  wife of James  Baker,  a Director of the Issuer;
(iv) 558,801 shares to Reynald G. Bonmati, the Chairman of the Board, President,
Treasurer  and a  Director  of the  Issuer,  in  repayment  of an advance to the
partnership  in the amount of  $311,706;  (v) 3,089  shares to Sandrine  Bonmati
Trust in  repayment  of an advance to the  partnership  in the amount of $1,723;
(vi) 21,767 shares to Chrystele Bonmati Trust, in repayment of an advance to the
partnership  in the  amount of  $12,142;  and (vii)  430,921  shares to  certain
partners  (individuals and entities) of Novatech Ventures otherwise unrelated to
the Issuer or its officers or directors.
<PAGE>
CUSIP NO. 656031-10-1                                    Page 7 of 11

ITEM 1.  SECURITY AND ISSUER.

         This  statement  relates to the  Common  Stock of the  Issuer,  Norland
Medical Systems, Inc. The principal executive office of the Issuer is located at
106 Corporate Park Drive, Suite 106, White Plains, New York 10604.

ITEM 2.  IDENTITY AND BACKGROUND.

         The Amended Statement is being filed jointly by Norland Partners,
Novatech  Management,  Bones and Albert S. Waxman.

         Norland Partners is a Delaware  limited  partnership with an address at
Premium Point, New Rochelle,  New York 10801. The principal  business of Norland
Partners  is that of a  private  investment  fund.  Norland  Partners  no longer
beneficially owns any shares of the Issuer. Accordingly,  pursuant to regulation
section  240.13d-2,  Norland  Partners is not  required  to make any  additional
filings  unless it  hereafter  becomes  the  beneficial  owner of more than five
percent of the class and is required to file pursuant to section 240.13d-1.

         The sole general partner of Norland Partners is Novatech Management,  a
Delaware  corporation with an address at Premium Point,  New Rochelle,  New York
10801. Mr. Bonmati,  whose residence address is Premium Point, New Rochelle, New
York 10801, and Dr. Waxman,  whose address is provided below, are the directors,
executive officers and stockholders of Novatech Management Corporation. Novatech
Management no longer  beneficially  owns any shares of the Issuer.  Accordingly,
pursuant to regulation section 240.13d-2, Novatech Management is not required to
make any additional  filings unless it hereafter becomes the beneficial owner of
more than five percent of the class and is required to file  pursuant to section
240.13d-1.

         Bones is a  Delaware  limited  liability  company  with an  address  at
Premium Point, New Rochelle,  New York 10801. The principal business of Bones is
that of a private  investment firm. The managing members of Bones are Reynald G.
Bonmati and Hans Schiessl.

         Albert S. Waxman is a United States citizen with an address at 137 East
Inlet Drive, Palm Beach,  Florida 33480. The principal  occupation or employment
of Dr. Waxman is that of Senior Managing Partner, Psilos Group Managers, LLC, an
investment  firm.  Dr.  Waxman is a  Director  of the  Issuer,  and a  principal
shareholder of Novatech  Management.  This is Dr. Waxman's  initial Schedule 13D
filing.


<PAGE>

CUSIP NO. 656031-10-1                                    Page 8 of 11

         During the past five years,  none of the foregoing  parties,  including
any of their  executive  officers  or  directors,  has (a) been  convicted  in a
criminal proceeding (excluding traffic violations or similar  misdemeanors),  or
(b) been party to a civil  proceeding  of a judicial or  administrative  body of
competent jurisdiction and as a result of such proceeding was or is subject to a
judgment,  decree or final order enjoining future  violations of, or prohibiting
or mandating activities subject to, federal or state securities laws, or finding
any violations with respect to such laws.

ITEM 3.  SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

         N/A

ITEM 4.  PURPOSE OF TRANSACTION.

         This Amendment is being filed as a result of the transactions described
above.  The reporting  persons have no present plans or proposals that relate to
or would result in or cause:

         (a)      the  acquisition  by any person of additional  securities of
                  the Issuer, or the disposition  of  securities of the Issuer;

         (b)      an  extraordinary  corporate  transaction,  such as a  merger,
                  reorganization or liquidation,  involving the Issuer or any of
                  its subsidiaries;

         (c)      a sale or transfer of a material amount of assets of the
                  Issuer or any of its subsidiaries;

         (d)      any change in the present  board of directors or management of
                  the Issuer,  including  any plans or  proposals  to change the
                  number or term of directors or to fill any existing  vacancies
                  on the board;

         (e)      any material change in the present capitalization or dividend
                  policy of the Issuer;

         (f)      any other material change in the Issuer's business or
                  corporate structure;

         (g)      changes  in  the  Issuer's  charter,   bylaws  or  instruments
                  corresponding  thereto or other  actions  which may impede the
                  acquisition of control of the Issuer by any person;


<PAGE>
CUSIP NO. 656031-10-1                                    Page 9 of 11

         (h)      a class of  securities  of the Issuer being  de-listed  from a
                  national  securities  exchange or to cease to be authorized to
                  be quoted in an interdealer  quotation  system of a registered
                  national securities association;

         (i)      a class of equity  securities of the Issuer becoming  eligible
                  for termination of registration  pursuant to Section  12(g)(4)
                  of the Securities Exchange Act of 1934; or

         (j)      any action similar to any of those enumerated above.

         The filing persons  reserve the right to adopt such plans and proposals
subject  to  applicable  regulatory  requirements,   if  any;  and  to  transfer
securities of the Issuer  directly  and/or sell  securities of the Issuer in the
open market.

ITEM 5.  INTEREST IN SECURITIES OF THE ISSUER.

         (a)      As  of  November  12,  1999,  there  were  25,956,278  shares
of  Common  Stock  of  the  Issuer outstanding.

                  (1) As of December 31, 1999,  Norland Partners has distributed
all of its 7,735,201  shares of Common Stock to its partners.  Norland  Partners
currently does not beneficially own any shares, or 0% of the outstanding  Common
Stock of the Issuer.

                  (2)  As of  December  31,  1999,  Novatech  Management,  which
acquired 2,975,106 shares of Common Stock from Norland Partners, distributed all
of its  shares,  including  369,049  shares  it  previously  owned,  to its  two
shareholders,   Albert  Waxman  and  Reynald  G.  Bonmati.  Novatech  Management
Corporation  currently  does  not  beneficially  own  and  shares,  or 0% of the
outstanding Common Stock of the Issuer.

                  (3) As of December 31, 1999, Bones acquired 847,454 additional
shares of Common Stock from Novatech Ventures.  Bones may currently be deemed to
beneficially  own  10,734,833  shares  of  the  Issuer's  Common  Stock,   which
represents 41.4% of the outstanding Common Stock.

                  (4) As of December 31, 1999, Albert Waxman acquired  1,685,578
shares when Novatech  Management  distributed  all of its shares between its two
shareholders.  Mr.  Waxman may  currently be deemed to be a beneficial  owner of
1,685,578  shares  of the  outstanding  Common  Stock  (or  6.5%  of  the  total
outstanding).

         (b) Norland  Partners has sole power to vote and dispose of 0 shares of
Common Stock and shared  power to vote and dispose of 0 shares of Common  Stock.
<PAGE>
CUSIP NO. 656031-10-1                                    Page 10 of 11

Novatech  Management  has sole  power to vote and  dispose of 0 shares of Common
Stock and shared  power to vote and dispose of 0 shares of Common  Stock.  Bones
has sole  power  to vote and  dispose  of  10,234,833  shares  of  Common  Stock
representing  39.43% of the  outstanding  Common  Stock and has,  as a result of
being the control  shareholder  of NNS BV,  shared  power to vote and dispose of
500,000  shares.  Mr.  Waxman  has sole power to vote and  dispose of  1,685,578
shares of Common Stock,  representing 6.49% of the total  outstanding,  and does
not have any shared power to vote and dispose of any additional shares.

         (c) There  have  been no  transactions  in  securities  of the  Company
effected during the past sixty days by the  undersigned  other than as described
herein.

         (d) Except as set forth in this Amended  Statement,  no other person is
known to have the  right to  receive  or the  power to  direct  the  receipt  of
dividends  from, or the proceeds from the sale of, the securities of, the Issuer
that are owned beneficially by the reporting persons.

         (e)  Norland  Partners  and  Novatech  Management  each  ceased  to  be
beneficial  owner of more than five  percent of the Common Stock on December 31,
1999.  Accordingly,  pursuant to Regulation  Section  240.13d-2,  neither is not
required to make any  additional  filings  unless either  hereafter  becomes the
beneficial  owner of more than five percent of the class and is required to file
pursuant to 240.13d-1. Item 5(e) is not applicable to Bones or Dr. Waxman.

ITEM 6.  CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS
         OR RELATIONSHIPS WITH RESPECT TO THE
         SECURITIES OF THE COMPANY

         Pursuant  to the Norland  Partners  Partnership  Agreement,  the shares
distributed by Norland Partners to its partners on December 31, 1999 were valued
at the average of the closing bid and ask prices for the last five  trading days
ending on the day of the  transfer.  Such shares  were  valued at  $0.55781  per
share.

ITEM 7.  MATERIAL TO BE FILED AS EXHIBITS.

         (a)  Exhibit 1 -  Joint Filing Agreement.



<PAGE>
                                                                   Page 11 of 11

                                   SIGNATURES

                  After  reasonable  inquiry and to the best of their  knowledge
and belief, each of Norland Partners, Novatech Management Corporation, Bones and
Albert S. Waxman  certifies that the  information set forth in this statement is
true, complete and correct.


Date: January 14, 2000

                             NORLAND PARTNERS, L.P.
                             By: Novatech Management Corporation,
                                 General Partner


                           By:Reynald G. Bonmati
                              _______________________
                              Reynald G. Bonmati
                              President

                              NOVATECH MANAGEMENT CORPORATION


                           By: Reynald G. Bonmati
                               _______________________
                               Reynald G. Bonmati
                               President


                               BONES, L.L.C.



                           By: Reynald G. Bonmati
                               ________________________
                               Reynald G. Bonmati
                               Managing Member


                           Albert S. Waxman
                           ____________________________
                           Albert S. Waxman





                                                                       EXHIBIT 1

                             JOINT FILING AGREEMENT

         In accordance  with the Rule  13d-1(k)(1)  under the  Securities Act of
1934,  the persons  named  below agree to the joint  filing on behalf of each of
them of a Schedule 13D (including amendments thereto) with respect to the Common
Stock of Norland Medical Systems,  Inc. and further agree that this Joint Filing
Agreement be included as an Exhibit to such joint filing.  In evidence  thereof,
the undersigned,  being duly authorized, hereby execute this Agreement this 11th
day of January, 2000.


                             NORLAND PARTNERS, L.P.
                             By: Novatech Management Corporation,
                                 General Partner


                           By:Reynald G. Bonmati
                              _______________________
                              Reynald G. Bonmati
                              President

                              NOVATECH MANAGEMENT CORPORATION


                           By: Reynald G. Bonmati
                               _______________________
                               Reynald G. Bonmati
                               President


                               BONES, L.L.C.



                           By: Reynald G. Bonmati
                               ________________________
                               Reynald G. Bonmati
                               Managing Member


                           Albert S. Waxman
                           _____________________________
                           Albert S. Waxman





© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission